February 25, 2026
The Huang Lab received support to advance preclinical development of PH102 for hepatocellular carcinoma, reinforcing the lab’s translational focus.
The Huang Lab was awarded an American Cancer Society EDS Accelerator Grant to support the preclinical development of PH102 for hepatocellular carcinoma.
The award strengthens the lab’s translational pipeline and supports the next phase of work needed to move this program toward broader development.
More news
Jun 15, 2026
The Huang Lab published a review in Hematological Oncology on the biological barriers limiting CAR T cell therapy in solid tumors and the engineering strategies to overcome them.
Read articleJun 10, 2026
Vincent Pham was named a 2026 Future Texas Business Legend by the Texas Business Hall of Fame, receiving the Carlos & Malú Alvarez Award.
Read articleMay 12, 2026
Alejandra Lorenzen will present Huang Lab work on a synthetic blood oxygen carrier (OcVe) at the AIM 2026 Health R&D Summit, where Huang Lab members and Abioremedi will meet partners.
Read article